Short Interest in Pasithea Therapeutics Corp. (NASDAQ:KTTA) Drops By 86.7%

Pasithea Therapeutics Corp. (NASDAQ:KTTA) was the recipient of a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 22,800 shares, a decline of 86.7% from the September 30th total of 171,300 shares. Based on an average trading volume of 920,600 shares, the short-interest ratio is currently 0.0 days. Currently, 2.8% of the shares of the company are short sold.

Pasithea Therapeutics Stock Down 8.4 %

Shares of NASDAQ KTTA traded down $0.34 during midday trading on Friday, hitting $3.70. The stock had a trading volume of 35,032 shares, compared to its average volume of 305,696. The company’s 50-day simple moving average is $4.57 and its 200 day simple moving average is $5.50. Pasithea Therapeutics has a fifty-two week low of $3.40 and a fifty-two week high of $17.40.

Pasithea Therapeutics (NASDAQ:KTTA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($3.71) EPS for the quarter.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.